Treating Ebola patients: A 'bottom up' approach using generic statins and angiotensin receptor blockers

International Journal of Infectious Diseases

Volumn 36, Issue , 2015, Pages 88-25

  Fedson, David S ^a   Rordam, Ole Martin ^b  

^a NONE   (France)

^b NONE   (Norway)

Author keywords

'Bottom up'; Angiotensin receptor blockers; Ebola; Endothelial dysfunction; Host response; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BIPHENYL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; TETRAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AFRICA; CHILD; EPIDEMIC; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA, WESTERN; ANGIOTENSIN RECEPTOR ANTAGONISTS; ATORVASTATIN CALCIUM; BIPHENYL COMPOUNDS; CHILD; DISEASE OUTBREAKS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; TETRAZOLES; YOUNG ADULT;

EID: 84934300285     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.04.019     Document Type: Short Survey

References (52)

1. West African Ebola epidemic after one year-slowing but not yet under control. N Engl J Med 2015, 372:584-587. WHO Ebola response team.
2. Sissoko D, Anglaret X, Malvy D, Folkesson E, Abdoul M, Shepherd S, et al. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Abstract 103-ALB. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, February 23-26, 2015.
3. Kreuels B., Wichmann D., Emmerich P., Schmidt-Chanasit J., de Heer G., Kluge S., et al. A case of severe Ebola virus infection complicated by Gram-negative septicemia. N Engl J Med 2014, 371:2394-2401.
4. Lyon G.M., Mehta A.K., Varkey J.B., Brantly K., Plyler L., McElroy A.K., et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014, 371:2402-2409.
5. Wolf T., Kann G., Becker S., Stephan C., Brodt H.R., de Leuw P., et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 2015, 385:1428-1435.
6. Zhou Q., Liao J.K. Pleotropic effects of statins-basic research and clinical perspectives. Circ J 2010, 74:818-826.
7. Di Raimondo D., Tuttolomondo A., Butta D., Miceli S., Licata G., Pinto A. Effects of ACE inhibitors and angiotensin receptor blockers on inflammation. Curr Pharmacol Des 2012, 18:4385-4413.
8. Margaritis M., Channon K.M., Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal 2014, 20:1198-1215.
9. Chen W., Pendyala S., Natarajan V., Garcia J.G., Jacobson J.R. Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol 2008, 295:L575-L583.
10. Xiao H.B., Xiong Q., Ping D., Zuo K.Q. Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity. PLoS One 2013, 8:e59233.
11. Bodor C., Nagy J.P., Vegh B., Nemeth A., Jenei A., MizraHousseini S., et al. Angiotensin II increases the permeability and PV-1 expression of endothelial cells. Am J Physiol Cell Physiol 2012, 302:C267-C276.
12. Bray M., Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003, 188:1613-1617.
13. Kortepeter M.G., Bausch D.G., Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011, 204(Suppl 3):S810-S816.
14. Page A.V., Liles W.C. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence 2013, 4:507-516.
15. Opal S.M., van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med 2014, 277:277-293.
16. Steinberg B.E., Goldenberg N.M., Lee W.L. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 2012, 93:2-15.
17. Rasmussen A.L., Okumura A., Ferris M.T., Green R., Feldmann F., Kelly S.M., et al. Host generic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 2014, 346:987-991.
18. Roca A., Afolabi M.O., Saidu Y., Kampmann B. Ebola: a holistic approach is required to achieve effective management and control. J Allergy Clin Immunol 2015, 135:856-867.
19. Mortensen E.M., Nakashima B., Cornell J., Copeland L.A., Pugh M.J., Anzueto A., et al. Population-based study of statins, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012, 55:1466-1473.
20. Vandermeer M.L., Thomas A.R., Kamimoto L., Reingold A., Gershman K., Meek J., et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012, 205:13-19.
21. Patel J.M., Snaith C., Thickett D.R., Linhartova L., Melody T., Hawkey P., et al. Randomized double-blind placebo-controlled trial of 40mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012, 16:R231.
22. Xu H., Ye X., Steibert H., Liu S.F. Selective blockade of endothelial NF-κB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. J Pathol 2010, 220:490-498.
23. Ceriello A., Assaloni R., Da Ros R., Maier A., Piconi L., Quagliaro L., et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress and inflammation in type 2 diabetic patients. Circulation 2005, 111:2518-2524.
24. Lee H.Y., Sakuma I., Ihm S.H., Goh C.W., Koh K.K. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014, 78:281-287.
25. Fedson D.S. A practical treatment for patients with Ebola virus disease. J Infect Dis 2015, 211:661-662.
26. Johansen L.M., Brannan J.M., Delos S.E., Shoemaker C.J., Stossel A., Lear C., et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2014, 5:190ra79.
27. Towner J.S., Rollin P.E., Bausch D.G., Sanchez A., Crary S.M., Vincent M., et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004, 78:4330-4341.
28. Chertow D.S., Kleine C., Ewards J.K., Scaini R., Giuliani R., Sprecher A. Ebola virus disease in West Africa-clinical manifestations and management. N Engl J Med 2014, 371:2054-2057.
29. McElroy A.K., Akondy R.S., Davis C.W., Ellebedy A.H., Mehta A.K., Kraft C.S., et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A 2015, 112:4719-4724.
30. Enserink M. Debate erupts on 'repurposed' drugs for Ebola. Science 2014, 345:718-719.
31. Hoenen T., Feldman H. Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol 2014, 12:80.
32. World Health Organization. Meeting of the Scientific and Technical Advisory Committee on Ebola experimental interventions-briefing note. WHO; November 13, 2014. Available at: (accessed 10.04.14). http://apps.who.int/medicines/ebola-treatment/scientific_tech_meeting/en/index.html.
33. Klatt N.R., Silvestri G., Hirsch V. Nonpathogenic simian immunodeficiency virus infections. Cold Spring Harb Perspect Med 2012, 2:a007153.
34. Kortepeter M.G., Lawler J.V., Honko A., Bray M., Johnson J.C., Purcell B.K., et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis 2011, 204(Suppl 3):S1000-S1010.
35. Piot P., Muyembe J.J., Edmunds W.J. Ebola in West Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis 2014, 14:1034-1035.
36. Médecins sans Frontières. Pushed to the limit and beyond: a year into the largest ever Ebola outbreak. MSF; 2015. Available at: (accessed 10.04.14). http://www.msf.org.uk/sites/uk/files/ebola_-_pushed_to_the_limit_and_beyond.pdf.
37. Petersen E., Maiga B. Guidelines for treatment of patients with Ebola virus disease are urgently needed. Int J Infect Dis 2015, 30:85-86. Available at: http://dx.doi.org/10.1016/j.ijid.2014.12.002 (accessed 10.04.14).
38. Bah E.I., Lamah M.C., Fletcher T., Jacob S.T., Brett-Major D.M., Sail A.A., et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. . N Engl J Med 2015, 372:40-47.
39. Fowler R.A., Fletcher T., Fischer W.A., Lamontagne F., Jacob S., Brett-Major D., et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 2014, 190:733-737.
40. Roberts I., Perner A. Ebola virus disease: clinical care and patient-centred research. Lancet 2014, 384:2001-2002.
41. Dunning J., Fischer W. Ebola: the battle plan must include specific treatments. Lancet 2015, 385:1373-1375.
42. Jacobs M., Beadsworth M., Schmid M., Tunbridge A. Provision of care for Ebola. Lancet 2014, 384:2105-2106.
43. Brown C., Kreuels B., Baker P., Baker T., Boyles T., Lado M., et al. Ebola and provision of critical care. Lancet 2015, 385:1392.
44. Murthy S. Ebola and provision of critical care. Lancet 2015, 385:1392-1393. on behalf of the Ebola Clinical Care Authors Group.
45. Fedson D.S., Dunnill P. From scarcity to abundance: pandemic vaccines and other agents for "have not" countries. J Public Health Policy 2007, 28:322-340.
46. Wong G., Qiu X., Olinger G.G., Kobinger G.P. Post-exposure therapy of filovirus infections. Trends Microbiol 2014, 22:456-463.
47. Marston H.D., Folkers G.K., Morens D.M., Fauci A.S. Emerging viral diseases: confronting threats with new technologies. Sci Transl Med 2014, 6:253ps10.
48. Morens D.M., Fauci A.F. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog 2013, 9:e1003467.
49. Fedson D.S. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013, 99:417-435.
50. Fedson D.S. How will physicians respond to the next influenza pandemic?. Clin Infect Dis 2014, 58:233-237.
51. Multiple treatments for Ebola virus disease (EVD). ClinicalTrials.gov, NIH, USA; 2015. Available at: (accessed 10.04.14). https://clinicaltrials.gov/ct2/show/NCT02380625.
52. Kupperschmidt K. As Ebola wanes, trials jockey for patients. Science 2015, 348:40.